https://www.targetedonc.com/view/fda-grants-accelerated-approval-to-talquetamab-for-rrmm
FDA Grants Accelerated Approval to Talquetamab for RRMM | Targeted Oncology - Immunotherapy,...
Oct 17, 2026 - Data from the phase 2 MonumenTAL-1 study support the accelerated approval of talquetamab in patients with relapsed/refractory who have received at least 4...
accelerated approvalfdagrantstalquetamabrrmm
https://www.journalonko.de/news/medizin/rr-mm-zulassung-talquetamab-eu
r/r MM: Zulassung von Talquetamab in der EU
Talquetamab, der erste bispezifische Antikörper, der auf GPRC5D abzielt, zeigt eine Gesamtansprechrate von über 70% beim r/r MM. Mehr dazu hier!
zulassungvontalquetamabder
https://bpno.no/artikler/the-first-in-class-antibody-talquetamab-show-a-high-clinical-response-rate-in-patients-with-relapsed-and-refractory-multiple-myeloma/
The first-in-class antibody talquetamab show a high clinical response rate in patients with...
Sep 1, 2023 - Talquetamab is a first-in-class bispecific immunoglobulin G4 antibody that binds to CD3 and GPRC5D for activating T cells to attack multiple myeloma cells. The...
first in classresponse rateantibodytalquetamabshow
https://www.cancer.gov/publications/dictionaries/cancer-drug/def/talquetamab
Definition of talquetamab-tgvs - NCI Drug Dictionary - NCI
Find technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes...
drug dictionarydefinitiontalquetamabtgvsnci